4,901 trials
Insomnia Disorder
Primary: Mean Change From Baseline in the Average Sleep Onset Latency (SOL) From Modified-Multiple Sleep Latency Test (M-MSLT) for Each Treatment in Treatment Periods 1 to 3…
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir) — -8.3; -7.8; -11.5; -10.9 ms
Hepatic Impairment
Primary: Cmax: Maximum Plasma Concentration of Lemborexant — 62.9; 48.7; 39.8 nanogram per milliliter (ng/mL)
Obstructive Sleep Apnea · Healthy Subjects
Primary: HV Cohort: Peripheral Oxygen Saturation (SpO2) During Total Sleep Time (TST) on Day 1 of Treatment — 95.34; 95.00; 95.07 percentage of oxygen saturation — p=0.099
Major Depressive Episode · Unipolar Depression · Bipolar Depression
Primary: The Hamilton Rating Scale for Depression-24 Item Version (HRSD-24) — 11.2; 16.6 score on a scale
Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of Lemborexant — 48.9; 46.6 nanogram per milliliter (ng/mL)
Advanced Solid Tumors
Primary: Treatment Phase Part A: AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for E7820 — 12500; 11500 nanogram*hour per milliliter (ng*hr/mL)
Alcohol Drinking
Primary: Safety/Tolerability of Study Medication. — 0 participants
Lymphoma, T-Cell, Peripheral · Lymphoma, T-Cell, Cutaneous
Primary: Safety of RP6530 — 0; 0; 0; 2 Participants
Healthy
Primary: Simulated Driving Performance in Healthy Participants as Measured by Standard Deviation of Lateral Position (SDLP) Using the Cognitive Research Corporation Driving…
Healthy
Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) — 299 nanograms per milliliter (ng/mL)
Recreational Drug Use · Prescription Drug Abuse (Not Dependent)
Primary: Pharmacodynamics (PD): Maximal Effect Score (Emax) of Bipolar Drug Liking Visual Analog Scale (VAS) Scores — 53.0; 85.4; 68.6; 73.3 millimeter (mm)
Migraine
Primary: Simulated Driving Performance in Healthy Participants as Measured by Standard Deviation of Lateral Position (SDLP) Using the Cognitive Research Corporation Driving…
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Healthy Volunteers
Primary: Period 1: Maximum Plasma Concentration (Cmax) of Pitavastatin — 23.8 ng/mL